Noninvasive assessment of characteristics of novel anti-HER2

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The

New Approach May Help Predict HER2+ Tumor Response to Treatment – Consult QD

Micromachines, Free Full-Text

Frontiers Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery

Diagnostics, Free Full-Text

Molecular and functional imaging in cancer-targeted therapy: current applications and future directions

Clinicopathological characteristics of the study population with

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study - eClinicalMedicine

HER2 low expression breast cancer subtyping and their correlation with prognosis and immune landscape based on the histone modification related genes

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial - The Lancet Oncology

Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model